Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Roche is presenting new Alzheimer's data at AAIC, showcasing a comprehensive approach to patient care. Ongoing Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrate rapid and robust amyloid plaque clearance, with 91% becoming amyloid PET negative and ARIA-E remaining below 5%. Designs for Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease are featured, with initiation planned for 2025. Roche also plans a new Phase III trial investigating trontinemab in preclinical Alzheimer's disease for those at risk of cognitive decline. New real-world data support Elecsys pTau217 as a standalone blood test comparable to PET scans for identifying amyloid pathology. This blood test offers improved patient access and reduced diagnosis time compared to current methods. Trontinemab's Brainshuttle technology enhances brain penetration for efficient amyloid plaque removal. Roche aims to enable earlier intervention and potentially prevent disease progression through advanced diagnostics and novel therapeutics. The company has over two decades of research dedicated to detecting and treating Alzheimer's early.